COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer (PARTIQoL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01617161
Recruitment Status : Recruiting
First Posted : June 12, 2012
Last Update Posted : September 9, 2020
University of Pennsylvania
National Cancer Institute (NCI)
Northwestern Medicine Chicago Proton Center
ProCure Proton Therapy Center
Washington University School of Medicine
University of Washington
Rutgers Cancer Institute of New Jersey
Provision Center for Proton Therapy
Mayo Clinic
University of Maryland, College Park
University Hospitals Cleveland Medical Center
University of Florida Proton Therapy Institute
Information provided by (Responsible Party):
Jason Efstathiou, Massachusetts General Hospital

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2026